Inicio>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Acetyltransferases>>CPTH2

CPTH2

Catalog No.GC39365

CPTH2 es un potente inhibidor de histona acetiltransferasa (HAT). CPTH2 inhibe selectivamente la acetilaciÓn de la histona H3 por Gcn5. CPTH2 induce la apoptosis y disminuye la invasividad de una lÍnea celular de carcinoma renal de células claras (ccRCC) a través de la inhibiciÓn de la acetiltransferasa p300 (KAT3B).

Products are for research use only. Not for human use. We do not sell to patients.

CPTH2 Chemical Structure

Cas No.: 357649-93-5

Tamaño Precio Disponibilidad Cantidad
10mg
130,00 $
Disponible
50mg
324,00 $
Disponible
100mg
510,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CPTH2 is a potent histone acetyltransferase (HAT) inhibitor and selectively inhibits the acetylation of histone H3 by recombinant human Gcn5 in a substrate-competive manner. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B)[1][2].

[1]. Cocco E, et al. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumoraggressiveness and target of KAT inhibitor CPTH2. Clin Epigenetics. 2018 Apr 4;10:44. [2]. Chimenti F, et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl)hydrazone. J Med Chem. 2009 Jan 22;52(2):530-6.

Reseñas

Review for CPTH2

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CPTH2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.